{
    "nctId": "NCT01741883",
    "briefTitle": "Side Effect Prevention Training (SEPT) for Nocebo Effects in Breast Cancer Patients",
    "officialTitle": "Clinical Application of Nocebo Research: Optimizing Expectations of Breast Cancer Patients to Prevent Nocebo Side Effects and Decrease of Quality of Life During Adjuvant Endocrine Therapy (DFG, NE 1635/2-1)",
    "overallStatus": "UNKNOWN",
    "conditions": "Female Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "PREVENTION",
    "enrollmentCount": 165,
    "primaryOutcomeMeasure": "Side Effects (General Assessment of Side Effects, GASE)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Women with estrogen receptor positive breast cancer scheduled to start first-line adjuvant endocrine therapy with Tamoxifen (+/- GnRH) or a third generation Aromatase inhibitor at the Breast Cancer Centre\n* Sufficient knowledge of German language and ability to give informed consent\n* Age of 18 and more\n\nExclusion Criteria:\n\n* Presence of a serious comorbid psychiatric condition (schizophrenia or addiction, severe depression or anxiety)\n* Presence of a life threatening comorbid medical condition",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}